<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00729430</url>
  </required_header>
  <id_info>
    <org_study_id>591</org_study_id>
    <secondary_id>R01HL091157-01</secondary_id>
    <nct_id>NCT00729430</nct_id>
  </id_info>
  <brief_title>Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging</brief_title>
  <acronym>OmegaREMODEL</acronym>
  <official_title>Prognostic, Anti-arrhythmic, and Ventricular Remodeling Effects of High Dose Fish Oil in Patients With a Recent Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Doctors use magnetic resonance imaging (MRI) to obtain detailed pictures of the inside of the
      body. This study will evaluate a new MRI technique in people who have recently had a heart
      attack. Researchers will also examine the effect of fish oil supplementation on heart health
      in study participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A new MRI technique to examine the heart was recently developed. In this study, researchers
      will use this new technique to evaluate the heart in people who have recently had a heart
      attack to determine whether a specific pattern of heart muscle damage is related to sudden
      cardiac death. This fatal condition, also known as cardiac arrest, occurs when the heart
      abruptly stops pumping blood to the body, resulting in loss of consciousness, absence of
      pulse, and a stop in breathing. The most common cause of sudden cardiac death is a heart
      attack.

      In addition to evaluating the new heart MRI technique, this study will also examine the
      effects of fish oil supplementation in people who have recently had a heart attack. Recent
      research has shown that omega-3 fatty acids, commonly found in fish oil, may be beneficial
      for people with heart conditions. Lastly, the study will determine whether specific
      biomarkers and genetic factors can help predict the likelihood of a person dying from sudden
      cardiac death after previously experiencing a heart attack.

      Apart from studying the likelihood of sudden cardiac death, This study will measure the
      change in structure and pumping function of the heart (known as ventricular remodeling) and
      this study will determine if the high dose of fish oil treatment will result in an
      improvement of the heart.

      This study will enroll people who have had a heart attack in the 2 to 4 weeks before study
      entry. At a baseline study visit, participants will undergo an MRI of their heart and
      complete an exercise stress test on a treadmill. A blood sample will be collected, and women
      will provide a urine sample for a pregnancy test. Questionnaires asking about diet, medical
      history, and emotions will also be completed. Participants will then be randomly assigned to
      receive either fish oil supplements or placebo on a daily basis for 6 months. Every 2 to 3
      months, study researchers will call participants to check on their health and progress. At a
      study visit at Month 6, participants will undergo repeat baseline testing. After this visit,
      study researchers will call participants every 6 months for 3 years to follow up on
      participants' health status.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Omega-3 Fatty Acids on Adverse Left Ventricular Remodeling</measure>
    <time_frame>Before and after study treatments</time_frame>
    <description>Measured as change in left ventricular end-systolic volume indexed to body surface area from baseline to post-treatment (6-months)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of Omega-3 Fatty Acids on Non-Infarct Myocardial Fibrosis</measure>
    <time_frame>Measured in the 3-year follow-up period after participant's last study visit</time_frame>
    <description>Measured as change in myocardial extracellular volume fraction of non-infarcted myocardium from baseline to post-treatment (6-months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Omega-3 Fatty Acids on Left Ventricular Ejection Fraction</measure>
    <time_frame>Measured in the 3-year follow-up period after participant's last study visit</time_frame>
    <description>Measured as change in left ventricular ejection fraction from baseline to post-treatment (6-months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Omega-3 Fatty Acids on Infarct Size</measure>
    <time_frame>Measured in the 3-year follow-up period after participant's last study visit</time_frame>
    <description>Measured as change in infarct size from baseline to post-treatment (6-months)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">358</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Death, Sudden, Cardiac</condition>
  <arm_group>
    <arm_group_label>Omega-3 Fatty Acids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a highly purified form of omega-3 fatty acids for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3 Fatty Acids (Fish Oil Supplements)</intervention_name>
    <description>4 grams of omega-3 fatty acids taken orally once per day for 6 months</description>
    <arm_group_label>Omega-3 Fatty Acids</arm_group_label>
    <other_name>Lovaza (GlaxoSmithKline)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets taken orally once per day for 6 months</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Corn oil placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Experienced a heart attack in the 2 to 4 weeks before study entry

          -  Lives in the greater Boston area or adjacent regions (within a 50-mile radius of
             Boston)

        Exclusion Criteria:

          -  Unable to undergo an MRI because of metallic implants (e.g., pacemakers, an
             implantable cardioverter defibrillator [AICD]) at time of study entry

          -  Active cancer or any other terminal illness with an expected survival rate of less
             than 6 months after study entry

          -  Significant kidney dysfunction with a glomerular filtration rate (GFR) of less than 60
             mL/min in the 2 weeks before study entry

          -  Inability to follow study procedures

          -  Pregnant

          -  Hemodynamic instability

          -  Urgent clinical need for a pacemaker or AICD

          -  Inaccessibility of medical records
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond Y. Kwong, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital, Shapiro Cardiovascular Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Yan AT, Shayne AJ, Brown KA, Gupta SN, Chan CW, Luu TM, Di Carli MF, Reynolds HG, Stevenson WG, Kwong RY. Characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Circulation. 2006 Jul 4;114(1):32-9. Epub 2006 Jun 26.</citation>
    <PMID>16801462</PMID>
  </reference>
  <results_reference>
    <citation>Heydari B, Abdullah S, Pottala JV, Shah R, Abbasi S, Mandry D, Francis SA, Lumish H, Ghoshhajra BB, Hoffmann U, Appelbaum E, Feng JH, Blankstein R, Steigner M, McConnell JP, Harris W, Antman EM, Jerosch-Herold M, Kwong RY. Effect of Omega-3 Acid Ethyl Esters on Left Ventricular Remodeling After Acute Myocardial Infarction: The OMEGA-REMODEL Randomized Clinical Trial. Circulation. 2016 Aug 2;134(5):378-91. doi: 10.1161/CIRCULATIONAHA.115.019949.</citation>
    <PMID>27482002</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2008</study_first_submitted>
  <study_first_submitted_qc>August 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2008</study_first_posted>
  <results_first_submitted>February 28, 2017</results_first_submitted>
  <results_first_submitted_qc>May 25, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 1, 2017</results_first_posted>
  <last_update_submitted>May 25, 2017</last_update_submitted>
  <last_update_submitted_qc>May 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Raymond Y. Kwong, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Heart Attack</keyword>
  <keyword>Sudden Cardiac Death</keyword>
  <keyword>Peri-infarct Zone</keyword>
  <keyword>Omega-3 Fatty Acids</keyword>
  <keyword>Biological Markers</keyword>
  <keyword>Cytogenetic Analysis</keyword>
  <keyword>Cardiac Arrest</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Death, Sudden</mesh_term>
    <mesh_term>Death, Sudden, Cardiac</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Plan to share data with GISSI Heart Failure group for pooling and meta-analysis</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>High Dose Omega-3 Fatty Acid Arm</title>
          <description>Participants will receive a highly purified form of omega-3 fatty acids for 6 months.
Omega-3 Fatty Acids (Fish Oil Supplements): 4 grams of omega-3 fatty acids taken orally once per day for 6 months</description>
        </group>
        <group group_id="P2">
          <title>Placebo Arm</title>
          <description>Participants will receive placebo for 6 months.
Placebo: Placebo tablets taken orally once per day for 6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="180"/>
                <participants group_id="P2" count="178"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
                <participants group_id="P2" count="128"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High Dose Omega-3 Fatty Acid Arm</title>
          <description>Participants will receive a highly purified form of omega-3 fatty acids for 6 months.
Omega-3 Fatty Acids (Fish Oil Supplements): 4 grams of omega-3 fatty acids taken orally once per day for 6 months</description>
        </group>
        <group group_id="B2">
          <title>Placebo Arm</title>
          <description>Participants will receive placebo for 6 months.
Placebo: Placebo tablets taken orally once per day for 6 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="180"/>
            <count group_id="B2" value="178"/>
            <count group_id="B3" value="358"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" spread="10"/>
                    <measurement group_id="B2" value="58" spread="10"/>
                    <measurement group_id="B3" value="59" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="180"/>
                    <measurement group_id="B2" value="178"/>
                    <measurement group_id="B3" value="358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effect of Omega-3 Fatty Acids on Adverse Left Ventricular Remodeling</title>
        <description>Measured as change in left ventricular end-systolic volume indexed to body surface area from baseline to post-treatment (6-months)</description>
        <time_frame>Before and after study treatments</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Omega-3 Fatty Acid Arm</title>
            <description>Participants will receive a highly purified form of omega-3 fatty acids for 6 months.
Omega-3 Fatty Acids (Fish Oil Supplements): 4 grams of omega-3 fatty acids taken orally once per day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Participants will receive placebo for 6 months.
Placebo: Placebo tablets taken orally once per day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Omega-3 Fatty Acids on Adverse Left Ventricular Remodeling</title>
          <description>Measured as change in left ventricular end-systolic volume indexed to body surface area from baseline to post-treatment (6-months)</description>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="16.6"/>
                    <measurement group_id="O2" value="1.2" spread="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Omega-3 Fatty Acids on Non-Infarct Myocardial Fibrosis</title>
        <description>Measured as change in myocardial extracellular volume fraction of non-infarcted myocardium from baseline to post-treatment (6-months)</description>
        <time_frame>Measured in the 3-year follow-up period after participant's last study visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Omega-3 Fatty Acid Arm</title>
            <description>Participants will receive a highly purified form of omega-3 fatty acids for 6 months.
Omega-3 Fatty Acids (Fish Oil Supplements): 4 grams of omega-3 fatty acids taken orally once per day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Participants will receive placebo for 6 months.
Placebo: Placebo tablets taken orally once per day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Omega-3 Fatty Acids on Non-Infarct Myocardial Fibrosis</title>
          <description>Measured as change in myocardial extracellular volume fraction of non-infarcted myocardium from baseline to post-treatment (6-months)</description>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="14"/>
                    <measurement group_id="O2" value="3.4" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Omega-3 Fatty Acids on Left Ventricular Ejection Fraction</title>
        <description>Measured as change in left ventricular ejection fraction from baseline to post-treatment (6-months)</description>
        <time_frame>Measured in the 3-year follow-up period after participant's last study visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Omega-3 Fatty Acids Arm</title>
            <description>Participants will receive a highly purified form of omega-3 fatty acids for 6 months.
Omega-3 Fatty Acids (Fish Oil Supplements): 4 grams of omega-3 fatty acids taken orally once per day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Participants will receive placebo for 6 months.
Placebo: Placebo tablets taken orally once per day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Omega-3 Fatty Acids on Left Ventricular Ejection Fraction</title>
          <description>Measured as change in left ventricular ejection fraction from baseline to post-treatment (6-months)</description>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="11"/>
                    <measurement group_id="O2" value="2.1" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Omega-3 Fatty Acids on Infarct Size</title>
        <description>Measured as change in infarct size from baseline to post-treatment (6-months)</description>
        <time_frame>Measured in the 3-year follow-up period after participant's last study visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Omega-3 Fatty Acids Arm</title>
            <description>Participants will receive a highly purified form of omega-3 fatty acids for 6 months.
Omega-3 Fatty Acids (Fish Oil Supplements): 4 grams of omega-3 fatty acids taken orally once per day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Participants will receive placebo for 6 months.
Placebo: Placebo tablets taken orally once per day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Omega-3 Fatty Acids on Infarct Size</title>
          <description>Measured as change in infarct size from baseline to post-treatment (6-months)</description>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.8" spread="39.9"/>
                    <measurement group_id="O2" value="-1.9" spread="57.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Measured in the 3-year follow-up period after participant's last study visit</time_frame>
      <desc>Adverse events were evaluated every 2 months during the 6-month study drug period by an investigator with conducted scripted telephone interviews with each patient. Tolerance to study drug, adverse events, and pill counts were also evacuated during these interviews.</desc>
      <group_list>
        <group group_id="E1">
          <title>High Dose Omega-3 Fatty Acids Arm</title>
          <description>Participants will receive a highly purified form of omega-3 fatty acids for 6 months.
Omega-3 Fatty Acids (Fish Oil Supplements): 4 grams of omega-3 fatty acids taken orally once per day for 6 months</description>
        </group>
        <group group_id="E2">
          <title>Placebo Arm</title>
          <description>Participants will receive placebo for 6 months.
Placebo: Placebo tablets taken orally once per day for 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <description>Clinically significant bleeding or drop in hematocrit levels.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction (Tongue Swelling)</sub_title>
                <description>One omega-3 fatty acid treated patient experienced tongue swelling 1 month after enrollment that necessitated study drug termination, which resulted in resolution of the patient’s symptoms.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Fishy Taste in Mouth</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="180"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="180"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was not powered to evaluate for clinical heart failure and hard cardiac outcomes. A prospective trial would be necessary to determine the effect of earlier and high-dose omega-3 fatty acid therapy on improving clinical outcomes.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Raymond Y. Kwong, Director of Cardiac Magnetic Resonance Imaging</name_or_title>
      <organization>Brigham and Women's Hospital</organization>
      <phone>857-307-1960</phone>
      <email>rykwong@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

